Feb. 18, 2021
Excision BioTherapeutics Secures $60 Million to Advance CRISPR-Based Gene Editing Constructs Developed at Temple into Clinical Trial for People Living with Chronic HIV Infection
By Katz Communications
Excision BioTherapeutics, Inc. (Excision) has secured $60 million in investor financing to advance […]
